The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in ...

A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local ...

NewBiologix, a technology innovation company pioneering efficient, cost-effective, and scalable production of viral vectors for gene and cell therapy, today released a scientific white paper outlining ...

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

The treatment, called MCO-010 (sonpiretigene isteparvovec), comprises a gene that codes for the ambient light-sensitive MCO protein carried by an adeno-associated virus (AAV) vector, which is ...

PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...

the two companies have identified numerous well-validated cytokines that could be the basis for additional locally administered genetic therapies using the HCAd platform. GQ Bio is pioneering a ...